- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04507828
Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multiple studies have evaluated the efficacy of SBRT in patients with early stage lung cancer. The original Indiana University phase II trial evaluating three fraction SBRT with a total dose of 60-66 Gy for T1 and T2 (<7cm) lesions and median follow up of 50.2 months revealed a 3-year local failure rate of 5.7%. Tumor size and location did not impact tumor recurrence. [3]. RTOG 0236, which was a multi-institutional phase II trial evaluating the efficacy of three fraction SBRT for patients with peripherally located tumors, reported that 3-year local control rate was 98% with a median overall survival of 4 years and overall survival at 3 years of 56%. Long- term results of RTOG 0236 revealed a 5-year local failure rate of 7% and a 5-year overall survival rate of 40% [4, 5]. In addition, a pooled analysis of two randomized trials (Randomized study to Compare CyberKnife to Surgical Resection in Stage I Non-small Cell Lung Cancer [STARS] and the Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage [IA] Lung Cancer [ROSEL]) comparing SBRT vs. lobectomy for operable stage I (T1-2aN0M0) NSCLC showed a 3-year overall survival for SBRT of 95% and for surgery of 79% (HR=0.14, p=0.037). There was no statistically significant difference between both groups in terms of 3-year rate of recurrence-free survival (HR = 0.69, p = 0.54) [5]. To evaluate the efficacy of SBRT (66 Gy in 3 fractions) compared to standard treatment (70 Gy in 35 fractions), 102 patients, with stage I inoperable NSCLC, were randomized to each treatment arm in the SPACE trial. The results were consistent with similar overall survival and progression free survival on both treatment groups. According to the TROG 09.02 CHISEL trial, stage I inoperable NSCLC patients treated with SBRT had superior local control of the primary disease (HR: 0.32) without an increase in major toxicity compared to patients treated with standard fractionation[6].
Pulmonary metastases frequently happen in patients with different types of cancer. Around 50% of patients who suffer from malignancy-related mortality have pulmonary metastasis at the time of autopsy [7]. In 1995, Hellman et al introduced the concept of oligometastases and the importance of aggressive surgical or ablative therapies to improve overall survival in this population [8]. As a result, SBRT technique has been widely used to treat pulmonary metastases. Multiple studies have evaluated this technique including a retrospective study evaluating 577 patients who undergo SBRT for pulmonary metastases that revealed 5-year local control of 46.3% and 5-year overall survival of 21.8% [9]. Based on the above findings, the researchers propose a prospective feasibility trial evaluating the combined DIBH-expiration planning and delivery technique in patients with lung tumors in close proximity to the chest wall who are candidates to receive lung SBRT per their standard care.
Based on the observed respiration dependent movement during CT simulation the study team will assign patients into two cohorts: A) Tumors with no overlap between respiratory states and B) Tumors with up to 50% overlap between respiratory states. For A, the study team will have a composite plan delivering half the dose using DIBH plan and the other half using the expiration phase plan for each fraction. For B) the radiation target will be subdivided into different zones with different zones receiving different prescriptions. The study plan will be compared to a standard plan specifically designed for the same patient. Researchers hypothesize that this technique will enable us to reduce chest wall V30 by 50% and deliver 54 Gy in 3 fractions while meeting all the dosimetric constraints. Cohorts A and B will be analyzed separately. Other dosimetric parameters will be evaluated in this trial.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Hospital / IU Simon Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age≥ 18 at time of consent
- Karnofsky Performance Status (KPS) > 40
- Ability to provide written informed consent and HIPAA authorization
- Clinical or pathological diagnosis of primary lung cancer or metastasis to the lung
- Tumors must be located within 2 cm from the chest wall, defined as the inner border of the 2-cm lung expansion volume (per TG101)
- Plan to receive Lung SBRT
Exclusion Criteria:
- Patients with tumors with > 50% overlap between respiratory states based on CT simulation will not be eligible for this study
- Previous radiation therapy to the same site per investigator discretion
- Inability to comply with treatment or standard of care follow up per investigator discretion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined DIBH-Expiration Planning Technique
Patients will undergo a 4D scan as well as a DIBH scan and an expiration breath hold scan.
In order to develop a combined DIBH-Expiration treatment plan, the DIBH scan, the expiration phase of the 4D scan or the expiration breath hold scan will be used.
If the radiation plan meets the coverage goals and normal tissue constraints, the patient will receive treatment using the new DIBH Planning Technique.
If coverage and normal tissue constraints are not met per protocol, the patient will be treated per standard of care and not on protocol.
Patients treated on protocol will undergo radiation treatment with SBRT for a total of 3 fractions and will receive each fraction no more frequently then every other day.
Patients will then be evaluated at 1 month after SBRT completion and every 3 months for 2 years
|
Different radiation plans will be generated-one using a DIBH scan with corresponding target and normal tissue contour and a second using an expiration scan with corresponding target and normal tissue contours.
The expiration scan can be an expiratory gating scan averaging the expiratory breathing phases or an expiration breath hold scan as determined based on patient performance during simulation and relative tumor displacement compared to the DIBH scan.
Then a third plan will be generated conceptually combining the two previous plans, named the DIBH-expiration composite plan.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in chest wall V30 using combined DIBH-expiration planning technique
Time Frame: 2 weeks (SBRT planning)
|
The percentage of patients with an at least 50% reduction in chest wall V30 using combined DIBH-expiration planning technique in comparison to DIBH or expiration gating alone in the same patient
|
2 weeks (SBRT planning)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients treated using DIBH planning technique
Time Frame: 8 weeks (treatment with SBRT)
|
Percentage of patients treated with 54 Gy in 3 fractions using our new technique, who did not meet constraints for three fraction treatments using standard planning delivery techniques
|
8 weeks (treatment with SBRT)
|
Chest wall toxicity
Time Frame: 1 year
|
Incidence of chest wall toxicity
|
1 year
|
Rib fracture
Time Frame: 1 year
|
Incidence of rib fracture (based on surveillance imaging)
|
1 year
|
Local control rate
Time Frame: 2 year
|
local control rates (defined as no tumor recurrence within 80% isodose line)
|
2 year
|
Time in treatment room
Time Frame: 8 weeks (completion of SBRT)
|
Amount of on-table time in treatment room
|
8 weeks (completion of SBRT)
|
Reduction in chest wall maximum dose
Time Frame: 2 weeks (SBRT planning)
|
The calculated mean average of dosimetric reduction in chest wall maximum dose
|
2 weeks (SBRT planning)
|
Evaluate lung dose
Time Frame: 2 weeks
|
Evaluation of mean lung dose
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tim Lautenschlager, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RAON-IIR-IUSCC-0711
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Treatment Planning using the DIBH Technique
-
University Medical Center GroningenTerminatedEsophageal CancerNetherlands
-
St. Justine's HospitalRecruiting
-
Hadassah Medical OrganizationUnknown
-
Medical University of ViennaUniversity of Mississippi Medical CenterCompletedInfertility, Female | Infertility of Tubal Origin | Fallopian Tube Occlusion | Uterus AbnormalAustria
-
Chang Gung Memorial HospitalCompletedDiabetic Foot UlcerTaiwan
-
University of ValenciaCompleted
-
Fernandez ZamoraRecruitingColorectal Cancer | Wound Infection | Incisional HerniaSpain
-
Daniel Rodriguez PerezInstitut d'Investigació Biomèdica de Bellvitge; Institut Català de la SalutRecruitingArthropathy of HipSpain
-
Mansoura UniversityRecruitingLearning Curve | Prostate Hyperplasia | LaserEgypt
-
Fudan UniversityTongji Hospital; Qilu Hospital of Shandong University; Tianjin Medical University... and other collaboratorsNot yet recruitingPancreatic Neuroendocrine Tumor | Solid Pseudopapillary Tumor of the Pancreas | Pancreatic Tumor, Benign